Oral desmopressin lyophilisate (MELT) for monosymptomatic enuresis: structured versus abrupt withdrawal

J Pediatr Urol. 2014 Feb;10(1):52-5. doi: 10.1016/j.jpurol.2013.05.021. Epub 2013 Jun 19.


Objective: To investigate whether a structured withdrawal program from a sublingual formulation of fast-melting oral desmopressin lyophilisate (MELT) is superior to a sudden withdrawal from this formulation in the treatment of monosymptomatic nocturnal enuresis.

Materials and methods: One hundred and three children presented to our pediatric nephrology outpatient clinic for bedwetting. Eighty-one children, aged between 5½ and 14 years (mean age 8.64 years), were treated with MELT at a dosage of 120 mcg a day. Responders were randomized to been withdrawn from therapy, after 3 months, abruptly or in a structured withdrawal program (60 mcg/day for 15 days and then 60 mcg every second evening for another 15 days). Main outcome parameter was relapse rate 1 month after the end of treatment. Relapse was defined as bedwetting occurring more than 2 nights per month after the 1-month treatment-free period.

Results: Relapse rate at 1 month after the end of treatment was 47.83% in the group on a structured program versus 45.83% in the abrupt termination group (p = 0.89).

Conclusion: Our study suggests that a structured withdrawal program from MELT therapy doesn't offer advantages compared to an abrupt termination in children with monosymptomatic nocturnal enuresis.

Keywords: Enuresis; Fast-melting oral desmopressin lyophilisate; Treatment.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Sublingual
  • Adolescent
  • Antidiuretic Agents / administration & dosage*
  • Child
  • Child, Preschool
  • Deamino Arginine Vasopressin / administration & dosage*
  • Enuresis / drug therapy*
  • Female
  • Humans
  • Male
  • Recurrence


  • Antidiuretic Agents
  • Deamino Arginine Vasopressin